An observational study in Hereditary Angioedema (HAE), sponsored by Takeda. Active, not recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Angioedemas, Hereditary by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Angioedemas, Hereditary · Takeda.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2023, is one of 21 observational ones, and was the 48th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →3 of the 58 studies in Angioedemas, Hereditary by Takeda are open now, in 3 countries. Recruiting first, the newest first:
Takeda · Sites in Korea, Republic of
Ages 12+
Takeda · Sites in Algeria
Ages 12+
Takeda · Sites in Egypt
Ages 1+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 24 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 43 observational studies indexed under Angioedemas, Hereditary.
Median enrollment 35 across the 36 interventional studies, 83 across the 21 observational. Of the 52 that completed or were terminated, 33 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
2 of the studies in Angioedemas, Hereditary by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05469789TakedaA Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | 2026-12-31 |
| NCT07293364TakedaA Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema | 2027-06-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Angioedemas, Hereditary by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab.
This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).
The population of this survey is all participants with HAE type I or II treated with lanadelumab in hospitals within the UK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Prevalent Cohort A will comprise eligible participants with HAE type I or II who have initiated treatment with lanadelumab at any point in time (i.e., all prevalent cases of exposure to lanadelumab). The total follow-up encompasses a 12-month pre-treatment period, and an up-to 24-month post-treatment period.
Other: No Intervention
Prevalent Cohort B will comprise eligible participants with HAE type I or II who have been treated with lanadelumab for \<12 months (i.e., the subset of participants from Prevalent Cohort A who initiated treatment with lanadelumab within \<12 months). The total follow-up encompasses a 12-month pre-treatment and an up to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
Other: No Intervention
Incident Cohort A will comprise eligible participants with HAE type I or II initiating treatment with lanadelumab at any time within the prospective data collection time period. The total follow-up encompasses a 12-month pre-treatment and an up-to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
Other: No Intervention
As it is an observational study, no intervention is administered in this study.
Number of Hereditary Angioedema (HAE) Attacks
Number of HAE attacks (both total \[including untreated\] and those requiring on-demand treatment) will be estimated across the pre- and post-treatment periods (that is, 12 months before and up to 24 months after initiation of treatment with lanadelumab).
Time frame: Up to approximately 3 years
Number of Participants Categorized by Their Demographic Characteristics
Demographic characteristics will include age, sex, and ethnic group at index.
Time frame: At index (lanadelumab treatment initiation day)
Number of Participants Categorized by Their Clinical Characteristics
Clinical characteristics will include categories of participant-reported age at onset of symptoms, age at diagnosis of HAE, duration of time from onset to diagnosis (i.e., the diagnostic delay), body mass index (BMI) (at index); comorbidities (pre and post index), history of laryngeal attacks (pre index), type of HAE (type I and II), and triggers for HAE symptoms onset (at index and post index). Index is defined as the lanadelumab treatment initiation day.
Time frame: Up to approximately 3 years
Number of Participants Categorized by Their Treatment Patterns
Treatment patterns will include categories of the summary of participant-reported duration of lanadelumab treatment, treatment dose given to participants, and participant with switching patterns with lanadelumab on occurence of HAE attacks.
Time frame: At and after index (lanadelumab treatment initiation day plus approximately 2 years)
Number of Participants Categorized by Their Patterns of Prophylactic Treatment
Patterns of prophylactic treatment will include categories of the summary of participant-reported use of brand and drug name, duration of treatment, dose of the treatment within same class of prophylactic treatments.
Time frame: Up to approximately 3 years
Compare the Number of Participants Categorized by Their Clinical Features of HAE Attacks Before and After Initiation of Lanadelumab
To compare the number clinical features of HAE attacks before and after initiation of lanadelumab. Clinical features of HAE attacks will include categories of summary of participant-reported time of attack, duration of attack, location (e.g., trunk, extremities, and larynx) of HAE attack, the severity (Grade 1 \[Mild\], Grade 2 \[Moderate\], and Grade 3 \[Severe\]) of HAE attack, and hospitalization due to the HAE attack.
Time frame: Up to approximately 3 years
Number of Self-Reported HAE Attacks
Time frame: Up to approximately 3 years
Number of Participants Categorized by Their Clinical Features of Self-Reported HAE Attacks
Clinical features of self-reported HAE attacks will include categories of summary of participant-reported time of attack, duration of attack, location (e.g., trunk, extremities, and larynx) of HAE attack, the severity (Grade 1 \[Mild\], Grade 2 \[Moderate\], and Grade 3 \[Severe\]) of HAE attack, symptoms of HAE attack (e.g., tiredness, abdominal pain, and abdominal swelling), and identified or suspected trigger(s) for the attack (e.g., contact with chemicals, drugs, or foods).
Time frame: Up to approximately 3 years
European Quality of Life 5 Dimensions 3-levels (EQ-5D-3L) Questionnaire Total Score
The EQ-5D-5L questionnaire will be used to record impact of HAE on participant's quality-of-life (QoL). The EQ-5D-5L is a descriptive system of Health-Related Quality-of-Life (HRQoL) states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take 1 of 5 responses. The responses record 5 levels of severity \[no problems, slight problems, moderate problems, severe problems, and extreme problems\] within a particular dimension. The scores will be the sum of scores from each dimension and can range from 5 (no problems) to 25 (extreme problems). Higher score indicated a worsening health condition.
Time frame: Up to approximately 2 years
EQ-5D-3L Visual Analogue Scale (VAS) Score
The EQ-5D-3L VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS is used as a quantitative measure of health outcome that reflect the participant's own judgement score, with a score of 0 as the worst and 100 as the best possible health.
Time frame: Up to approximately 2 years
Angioedema Quality of Life (AE-QoL) Total Scores
AE-QoL is a self-administered instrument designed to measure HRQoL in adult participants with recurrent angioedema. The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fears/shame, and food, Each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).
Time frame: Up to approximately 2 years
Angioedema Quality of Life (AE-QoL) Domain Scores
AE-QoL is a self-administered instrument designed to measure HRQoL in adult participants with recurrent angioedema. The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fears/shame, and food, Each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).
Time frame: Up to approximately 2 years
Number of Participants With HAE-related Health Care Resource Utilization (HCRU)
Healthcare resources used during medical encounters include in and out-patient visits to physicians, hospital admissions, in and out-patient emergency care, and in and out-patient clinical examinations and tests.
Time frame: Up to approximately 3 years
Angioedema Control Test (AECT) Total Score
The AECT is used to assess participants with recurrent angioedema. The test uses a questionnaire with 4 items, each of which has 5 options and is used to measure the participant's current disease control. HAE control score will be recorded with 5 levels of answers \[1=very often, 2=often, 3=sometimes, 4=seldom, 5=not at all\] to the following questions: 1) In the last 3 months, how often have you had angioedema? 2) In the last 3 months, how much has your QoL been affected by angioedema? 3) In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4) In the last 3 months, how well has your angioedema been controlled by your therapy?
Time frame: Up to approximately 2 years
Angioedema Control Test (AECT) Domain Score
The AECT is used to assess participants with recurrent angioedema. The test uses a questionnaire with 4 items, each of which has 5 options and is used to measure the participant's current disease control. HAE control score will be recorded with 5 levels of answers \[1=very often, 2=often, 3=sometimes, 4=seldom, 5=not at all\] to the following questions: 1) In the last 3 months, how often have you had angioedema? 2) In the last 3 months, how much has your QoL been affected by angioedema? 3) In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4) In the last 3 months, how well has your angioedema been controlled by your therapy?
Time frame: Up to approximately 2 years
Treatment Satisfaction Questionnaire for Medication (TSQM) Total Score
The TSQM comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100.
Time frame: Up to approximately 2 years
Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Score
The TSQM comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100.
Time frame: Up to approximately 2 years
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.